We have observed
4 EP applications
Robert Edward Perry
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
December 17, 2012).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
The therapeutic use of tetrathiomolybdate
Use of amisulpride for treating chemotherapy-induced nausea and vomiting
Tetrathiomolybdate for use in the treatment of ischemia-reperfusion injury of the heart
TETRATHIOMOLYBDATE FOR USE IN THE TREATMENT OF ISCHEMIA-REPERFUSION INJURY OF THE HEAD OR BRAIN